Increased plasma mannose binding lectin levels are associated with bronchiolitis obliterans after lung transplantation

Respiratory Research

Isabel P Neuringer⁴  Stephen L Tilley¹  Ayorinde A Medaiyese²  Robert M Aris¹  Steven J Budd³ 

[1] Division of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill, NC, USA;Pikeville Medical Cen, Pikeville, KY, USA;Protochips, Raleigh, NC, USA;Pulmonary and Critical Care Unit, Massachusetts General Hospital, 148 Bulfinch Bldg., 55 Fruit Street, Boston, MA, 02114, USA

关键词: Bronchiolitis obliterans syndrome;    Lung transplantation;    Mannose binding lectin;   

Others  :  1146829
DOI  :  10.1186/1465-9921-13-56

 received in 2011-11-10, accepted in 2012-04-09,  发布年份 2012

【 摘 要 】

Background

Long-term lung allograft survival is limited by bronchiolitis obliterans syndrome (BOS). Mannose binding lectin (MBL) belongs to the innate immune system, participates in complement activation, and may predispose to graft rejection. We investigated mannose binding (MBL) during cold ischemia and in tissue samples from explanted lungs with BOS, and assessed MBL and complement proteins in plasma post-lung transplantation relative to BOS staging.

Methods

MBL was detected by immunohistochemistry lung tissue at the time of cold ischemia and in samples with BOS. MBL was assayed in the peripheral blood of 66 lung transplant patients transplanted between 1990–2007.

Results

MBL localized to vasculature and basement membrane during cold ischemia and BOS. Patients further out post-lung transplant > 5 years (n = 33), had significantly lower levels of MBL in the blood compared to lung transplant patients < 5 years with BOS Op-3 (n = 17), 1738 ± 250 ng/ml vs 3198 ± 370 ng/ml, p = 0.027, and similar levels to lung transplant patients < 5 years with BOS 0 (n = 16), 1738 ± 250 ng/ml vs 1808 ± 345 ng/ml. MBL levels in all BOS 0 (n = 30) vs. all BOS Op-3 (n = 36) were 1378 ± 275 ng/ml vs. 2578 ± 390 ng/ml, p = 0.001, respectively. C3 plasma levels in BOS 0 (n = 30) vs. BOS Op-3 (n = 36) were 101 ± 19.8 mg/ml vs. 114 ± 25.2 mg/ml, p = 0.024, respectively.

Conclusions

MBL localizes within the lung during graft ischemia and BOS, higher levels of plasma MBL are associated with BOS Op-3 and < 5 years post-transplant, and higher level of plasma complement protein C3 was associated with BOS Op-3 clinical status. MBL may serve as a biomarker for poorer outcome post-lung transplantation.

【 授权许可】

   
2012 Budd et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Corris PA: Lung transplantation. Bronchiolitis obliterans syndrome. Chest Surg Clin N Am 2003, 13:543-557.
• [2]McDyer JF: Human and murine obliterative bronchiolitis in transplant. Proc Am Thorac Soc 2007, 4:37-43.
• [3]Shilling RA, Wilkes DS: Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond. Am J Transplant 2009, 9:1714-1718.
• [4]Belperio JA, Weigt SS, Fishbein MC, Lynch JP: Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc 2009, 6:108-121.
• [5]Takemoto SK, Zeevi A, Feng S, et al.: National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004, 4:1033-1041.
• [6]Magro CM, Abbas AE, Seilstad K, Pope-Harman AL, Nadasdy T, Ross P: C3d and the septal microvasculature as a predictor of chronic lung allograft dysfunction. Hum Immunol 2006, 67:274-283.
• [7]Miller GG, Destarac L, Zeevi A, et al.: Acute humoral rejection of human lung allografts and elevation of C4d in bronchoalveolar lavage fluid. Am J Transplant 2004, 4:1323-1330.
• [8]Magro CM, Deng A, Pope-Harman A, et al.: Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis. Transplantation 2002, 74:1273-1280.
• [9]Angaswamy N, Saini D, Ramachandran S, et al.: Development of antibodies to HLA precedes development of antibodies to MICA and are significantly associated with development of chronic rejection following human lung transplantation. Hum Immunol 2010, 71:560-565.
• [10]Pastva AM, Wright JR, Williams KL: Immunomodulatory roles of surfactant proteins A and D: implications in lung disease. Proc Am Thorac Soc 2007, 4:252-257.
• [11]Meloni F, Salvini R, Bardoni AM, et al.: Bronchoalveolar lavage fluid proteome in bronchiolitis obliterans syndrome: possible role for surfactant protein A in disease onset. J Heart Lung Transplant 2007, 26:1135-1143.
• [12]Endo Y, Takahashi M, Fujita T: Lectin complement system and pattern recognition. Immunobiology 2006, 211:283-293.
• [13]Downing I, Koch C, Kilpatrick DC: Immature dendritic cells possess a sugar-sensitive receptor for human mannan-binding lectin. Immunology 2003, 109:360-364.
• [14]Downing I, MacDonald SL, Turner ML, Kilpatrick DC: Detection of an autologous ligand for mannan-binding lectin on human B lymphocytes. Scand J Immunol 2005, 62:507-514.
• [15]Thiel S, Vorup-Jensen T, Stover CM, et al.: A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997, 386:506-510.
• [16]Dahl MR, Thiel S, Matsushita M, et al.: MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 2001, 15:127-135.
• [17]Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T: Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J Immunol 2000, 165:2637-2642.
• [18]Bernig T, Taylor JG, Foster CB, Staats B, Yeager M, Chanock SJ: Sequence analysis of the mannose-binding lectin (MBL2) gene reveals a high degree of heterozygosity with evidence of selection. Genes Immunity 2004, 5:461-476.
• [19]Schlapbach LJ, Aebi C, Otth M, Leibundgut K, Hirt A, Ammann RA: Deficiency of Mannose-Binding Lectin-Associated Serine Protease-2 Associated With Increased Risk of Fever and Neutropenia in Pediatric Cancer Patients. Pediatr Infect Dis J 2007, 26:989-994.
• [20]van Till JW, Modderman PW, de Boer M, Hart MH, Beld MG, Boermeester MA: Mannose-Binding Lectin deficiency facilitates abdominal yeast infection in patients with secondary peritonitis. Clin Vaccine Immunol 2008, 15:65-70.
• [21]Ribeiro LZ, Tripp RA, Rossi LM, Palma PV, Yokosawa J, Mantese OC, Oliveira TF, Nepomuceno LL, Queiróz DA: Serum Mannose-Binding Lectin Levels are Linked with Respiratory Syncytial Virus (RSV) Disease. J Clin Immunol 2008, 28:166-173.
• [22]Aoyagi Y, Adderson EE, Rubens CE, et al.: L-ficolin/Mannose-Binding Lectin-Associated Serine Protease Complexes Bind to Group B Streptococci Largely through N-Acetylneuraminic Acid of Capsular Polysaccharide, and Activate the Complement Pathway. Infect Immun 2008, 76:179-188.
• [23]Peterslund NA, Koch C, Jensenius JC, Thiel S: Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001, 358:637-638.
• [24]Mullighan CG, Heatley S, Doherty K, et al.: Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood 2002, 99:3524-3529.
• [25]Garred P, Pressler T, Madsen HO, et al.: Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999, 104:431-437.
• [26]Bohlson SS, Fraser DA, Tennr AJ: Complement proteins C1q and MBL are pattern recognition molecules that signal immediate and long-term protective immune functions. Mol Immunol 2007, 44:33-43.
• [27]Walsh MC, Bourcier T, Takahashi K, et al.: Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 2005, 175:541-546.
• [28]Hanse TK, Tarnow L, Thiel S, Steffensen R, Stehouwer CD, Schalkwijk CG, Parving HH, Flyvbjerg A: Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 2004, 53:1570-1576.
• [29]Zhang M, Takahashi K, Alicot EM, et al.: Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J Immunol 2006, 177:4727.
• [30]Zhang M, Carroll MC: Natural antibody mediated innate autoimmune response. Mol Immunol 2007, 44:103-110.
• [31]Hart ML, Ceonzo KA, Shaffer LA, et al.: Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol 2005, 174:6373-6380.
• [32]de Vries B, Walter SJ, Peutz-Kootstra CJ, Wolfs TG, van Heurn LW, Buurman WA: The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol 2004, 165:1677-1688.
• [33]Berger SP, Roos A, Mallat MJ, et al.: Low pretransplantation mannose-binding lectin levels predict superior patient and graft survival after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol 2007, 18:2416-2422.
• [34]Berger SP, Roos A, Mallat MJ, Fujita T, de Fijter JW, Daha MR: Association between mannose-binding lectin levels and graft survival in kidney transplantation. Am J Transplant 2005, 5:1361-1366.
• [35]Kwakkel-van Erp JM, Paantjens AW, van Kessel DA, Grutters JC, van den Bosch JM, van de Graaf EA, Otten HG: Mannose binding lectin deficiency linked to cytomegalovirus (CMV) reactivation and survival in lung transplantation. Clin Exp Immunol 2011, 165:410-416.
• [36]Carroll KE, Dean MM, Heatley SL, Meehan AC, Mifsud NA, Kotsimbos TC, Snell GI, Westall GP: High levels of mannose-binding lectin are associated with poor outcomes after lung transplantation. Transplantation 2011, 91:1044-1049.
• [37]Hodge S, Dean M, Hodge G, Holmes M, Reynolds PN: Decreased efferocytosis and mannose binding lectin in the airway in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2011, 30:589-595.
• [38]Wasowska B: Mechanisms involved in antibody and complement-mediated allograft rejection. Immunol Res 2010, 47:25-44.
• [39]Castellano G, Melchiorre R, Loverre A, et al.: Therapeutic targeting of classical and lectin pathways of complement protects form ischemia-reperfusion-induced renal damage. Am J Pathol 2010, 176:1648-1659.
• [40]de Vries B, Walter SJ, Peutz-Kootstra CJ, Wolfs TG, van Heum LW, Buurman WA: The mannose-binding lectin pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol 2004, 165:1677.
• [41]Imai N, Nishi S, Alchi B, et al.: Immunohistochemical evidence of activated lectin pathway in kidney allografts with peritubular capillary C4d deposition. Nephrol Dial Transplant 2006, 21:2589-2595.
• [42]Murata K, Fox-Talbot K, Qian Z, et al.: Synergistic deposition of C4d b complement-activating and non-activating antibodies in cardiac transplants. Am J Transplant 2007, 7:2605-2614.
• [43]Bouwman LH, Roos A, Terpstra OT, et al.: Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology 2005, 129:408-414.
• [44]Fildes JE, Shaw SM, Walker AH, et al.: Mannose-binding lectin deficiency offers protection from acute graft rejection after heart transplantation. J Heart Lung Transplant 2008, 27:1353-1356.
• [45]Munster JM, van der Bij W, Breukink MB, et al.: Association between donor MBL promoter haplotype and graft survival and the development of BOS after lung transplantation. Transplantation 2008, 86:1857-1863.
• [46]Nadar SK, Lip GY: New insights into complement C3 and inflammation in hypertension. J Human Hypertens 2007, 21:261-263.
• [47]Sampietro T, Neglia D, Bionda A, et al.: Inflammatory markers and serum lipids in idiopathic dilated cardiomyopathy. Am J Cardiol 2005, 96:1718-1720.
• [48]von Haehling S, Schefold JC, Lainscak M, Doehner W, Anker SD: Inflammatory biomarkers in heart failure revisited:much more than innocent bystanders. Heart Fail Clin 2009, 5:549-560.
• [49]Marten A, Buchler MW, Werft W, Wente MN, Kirschfink M, Schmidt J: Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology. J Immunother 2010, 33:219-224.
• [50]Hecker LA, Edwards AO, Ryu E, et al.: Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet 2010, 19:209-215.
• [51]Chalmers JD, Fleming GB, Hill AL, Kilpatrick DC: Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: A review and meta-analysis. Glycobiology 2011, 21:271-282.
• [52]Ibernon M, Moreso F, Moreno JM, et al.: Low serum mannose-binding lectin as a risk factor for new onset diabetes mellitus after renal transplantation. Transplantation 2009, 88:272-278.
• [53]Nauta AJ, Raaschpu-Jensen N, Roos A, et al.: Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol 2003, 33:2853-2863.
• [54]Lacroix M, Dumestre-Perard C, Schoehn G, et al.: Residue Lys57 in the collagen-like region of human L-ficolin and its counterpart Lys47 in H-ficolin play a key role in the interaction with mannan-binding lectin-associated serine proteases and the collectin receptor calreticulin. J Immunol 2009, 182:456-465.
• [55]Fu H, Liu C, Flutter B, Tao H, Gao B: Calreticulin maintains the low threshold of peptide requirement for efficient antigen presentation. Mol Immunol 2009, 46:3198-3206.
• [56]Ling S, Pi X, Holoshitz J: The rheumatoid arthritis shared epitope triggers innate immune signaling via cell surface calreticulin. J Immunol 2007, 179:6359-6367.
• [57]Green DR, Ferguson T, Zitvogel L, Kroemer G: Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009, 9:353-363.